# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2022 Earnings Results

**Report date:** 2022-05-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2022

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.06%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.49 | N/A | +22.59% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's current trajectory while acknowledging market challenges. They reiterated their commitment to innovation and growth.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining a robust pipeline for future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, which likely contributed to the slight stock increase. However, the lack of revenue data and guidance may leave investors cautious. The stock's modest reaction suggests that while the EPS beat is positive, investors are looking for more comprehensive insights into future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2022_